Routine follow-up based on RECIST guidelines on patients with recurrence and stage IV cancer undergoing a combination of immunotherapy using immature dendritic cells (iDC) and conventional therapies.

Routine follow-up based on RECIST guidelines on patients with recurrence and stage IV cancer undergoing a combination of immunotherapy using immature dendritic cells (iDC) and conventional therapies. - Routine follow-up on patients with recurrence and stage-IV cancer undergoing a combination of immunotherapy and conventional therapies.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009375

Enrollment

1000

Registered

2012-11-21

Start date

2007-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage-IV and recurrence cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients with recurrence and stage-IV who have solid tumors

Exclusion criteria

Exclusion criteria: Blood cancer patients

Design outcomes

Primary

Measure	Time frame
Evaluation using RECIST 6 weeks after a course, then every 3 months during the first year, every 6 months in the 2nd year, and once a year after the 3rd year.	—

Countries

Japan,Asia(except Japan)

Outcome results